Compare CLWT & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | BIVI |
|---|---|---|
| Founded | 1971 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 12.7M |
| IPO Year | 1996 | 2013 |
| Metric | CLWT | BIVI |
|---|---|---|
| Price | $1.45 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.26 |
| AVG Volume (30 Days) | ★ 1.4M | 227.2K |
| Earning Date | 04-30-2026 | 11-09-2026 |
| Dividend Yield | ★ 9.39% | N/A |
| EPS Growth | N/A | ★ 74.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $0.82 |
| 52 Week High | $2.68 | $3.79 |
| Indicator | CLWT | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 29.54 |
| Support Level | $1.46 | $1.15 |
| Resistance Level | $1.74 | $1.32 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 23.85 | 4.17 |
Euro Tech Holdings Co Ltd is mainly a distributor of a wide range of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies, and power generation equipment, including recorders and power quality analyzers. The Company acts as an exclusive or non-exclusive distributor for manufacturers of such equipment to commercial customers and governmental agencies in Hong Kong and mainland China, as well as commercial customers in Macau. It has two operating segments: Trading and manufacturing, which generate maximum revenue and act as a distributor of water treatment equipment, laboratory instruments, analyzers, test kits, related supplies, and power generation equipment; and the Engineering segment. The Company generates maximum revenue from the PRC.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.